Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism
Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. G Pugliese , F Pricci , G Romeo , F Pugliese , P Mené , S Giannini , B Cresci , G Galli , C M Rotella , H Vlassara and U Di Mario Department of Experimenta...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 46; no. 11; pp. 1881 - 1887 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
American Diabetes Association
01.11.1997
|
Online Access | Get full text |
Cover
Loading…
Summary: | Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated
mechanism.
G Pugliese ,
F Pricci ,
G Romeo ,
F Pugliese ,
P Mené ,
S Giannini ,
B Cresci ,
G Galli ,
C M Rotella ,
H Vlassara and
U Di Mario
Department of Experimental Medicine, 2nd Institute of Internal Medicine, La Sapienza University, Rome, Italy.
Abstract
Enhanced advanced glycosylation end product (AGE) formation has been shown to participate in the pathogenesis of diabetes-induced
glomerular injury by mediating the increased extracellular matrix (ECM) deposition and altered cell growth and turnover leading
to mesangial expansion. These effects could be exerted via an AGE-receptor-mediated upregulation of growth factors, such as
the IGFs and transforming growth factor-beta (TGF-beta). We tested this hypothesis in human and rat mesangial cells grown
on nonglycated or native bovine serum albumin (BSA), glycated BSA with AGE formation (BSA-AGE), or glycated BSA in which AGE
formation was prevented by the use of aminoguanidine (BSA-AM), in the presence or absence of an antibody, alpha-p60, directed
against the p60/OST protein named AGE-receptor 1 (AGE-R1), or normal control (pre-immune) serum. The mRNA and/or protein levels
of IGF-I, IGF-II, IGF receptors, IGF binding proteins (IGFBPs), TGF-beta1 and the ECM components fibronectin, laminin, and
collagen IV were measured, together with cell proliferation. Both human and rat mesangial cells grown on BSA-AGE showed increased
IGF-I and total and bioactive TGF-beta medium levels and enhanced IGF-I, IGF-II, and TGF-beta1 gene expression, compared with
cells grown on BSA, whereas total IGFBP and IGFBP-3 medium content, IGF receptor density and affinity, and IGF-I receptor
transcripts were unchanged. Moreover, cells grown on BSA-AGE showed increased ECM protein and mRNA levels versus cells cultured
on BSA, whereas cell proliferation was unchanged in human mesangial cells and slightly reduced in rat mesangial cells. Growing
cells on BSA-AM did not affect any of the measured parameters. Co-incubation of BSA-AGE with anti-AGE-R1, but not with pre-immune
serum, prevented AGE-induced increases in IGF-I, TGF-beta1, and ECM production or gene expression; anti-AGE-R1 also reduced
growth factor and matrix synthesis in cells grown on BSA. These results demonstrate that mesangial IGF and TGF-beta1 synthesis
is upregulated by AGE-modified proteins through an AGE-receptor-mediated mechanism. The parallelism with increased ECM production
raises the speculation that the enhanced synthesis of these growth factors resulting from advanced nonenzymatic glycation
participates in the pathogenesis of hyperglycemia-induced mesangial expansion. |
---|---|
ISSN: | 0012-1797 1939-327X 0012-1797 |
DOI: | 10.2337/diabetes.46.11.1881 |